| Diabetes Mellitus, Non-Insulin-Dependent
Cycloset vs Victoza
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Cycloset vs Victoza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVictoza has a higher rate of injection site reactions vs Cycloset based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Victoza but not Cycloset, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cycloset
Victoza
At A Glance
Oral
Daily
Dopamine D2 receptor agonist
SC injection
Daily
GLP-1 receptor agonist
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent 1.6 mg to 4.8 mg once daily within 2 hours after waking in the morning with food; initiate at 0.8 mg, increase by one tablet per week to maximal tolerated dose; limit to 1.6 mg daily with moderate CYP3A4 inhibitors; avoid with strong CYP3A4 inhibitors.
Diabetes Mellitus, Non-Insulin-Dependent, Cardiovascular Diseases (Adults) Start at 0.6 mg SC once daily for one week, then increase to 1.2 mg once daily; if additional glycemic control is required, increase to 1.8 mg once daily (maximum) after at least one week at 1.2 mg.
Diabetes Mellitus, Non-Insulin-Dependent (Pediatric >= 10 years) Start at 0.6 mg SC once daily; increase in 0.6 mg increments after at least one week on the current dose; maximum recommended dose is 1.8 mg once daily.
Contraindications
- Known hypersensitivity to bromocriptine, ergot-related drugs, or any excipient in CYCLOSET
- Syncopal migraine
- Postpartum patients
- Lactating patients
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity reaction to liraglutide or any excipient in VICTOZA
Adverse Reactions
Most common (>=5%) Nausea, fatigue, vomiting, headache, dizziness, rhinitis, constipation, sinusitis, diarrhea, asthenia, somnolence, dyspepsia, amblyopia, anorexia
Serious Hypotension, psychotic disorders, somnolence, syncope, fibrotic-related complications, cardiovascular events (myocardial infarction, stroke)
Postmarketing Hallucinations, retroperitoneal fibrosis, pulmonary fibrosis, pleural effusion, pericarditis, pericardial effusions, cardiac valvulopathy, psychotic and psychiatric disorders, impulse control/compulsive behaviors, neuroleptic-like malignant syndrome
Most common (>=5%) Nausea, diarrhea, headache, nasopharyngitis, vomiting, decreased appetite, dyspepsia, upper respiratory tract infection, constipation, back pain
Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, dehydration, elevations of liver enzymes, hyperbilirubinemia, cholestasis, cholecystitis, cholelithiasis, hepatitis, angioedema, anaphylactic reactions, pruritus, medullary thyroid carcinoma, dysgeusia, dizziness, dysesthesia, pulmonary aspiration, acute renal failure, increased serum creatinine, cutaneous amyloidosis, alopecia
Pharmacology
CYCLOSET (bromocriptine mesylate) is a sympatholytic dopamine D2 receptor agonist; timed morning administration in type 2 diabetes is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia without raising plasma insulin levels.
GLP-1 receptor agonist; liraglutide is an acylated human GLP-1 analog (97% amino acid sequence homology to endogenous human GLP-1(7-37)) that stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, and delays gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cycloset
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (2/12) · Qty limit (6/12)
Victoza
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Cycloset
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Victoza
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Cycloset
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Victoza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cycloset.
No savings programs available for Victoza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyclosetView full Cycloset profile
VictozaView full Victoza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.